Brief: Hansa Biopharma Announces Reimbursement In The Netherlands Of Idefirix

Hansa Biopharma AB

02/08/2021 07:03

Aug 2 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * HANSA BIOPHARMA ANNOUNCES REIMBURSEMENT IN THE NETHERLANDS
OF
IDEFIRIX ®  (IMLIFIDASE) AS DESENSITIZATION TREATMENT FOR HIGHLY
SENSITIZED KIDNEY TRANSPLANT PATIENTS
    * COMMERCIAL LAUNCH ACTIVITIES THROUGHOUT EUROPE ARE
UNDERWAY AS
PLANNED
    * FIRST AGREEMENTS AROUND REIMBURSEMENT AND FUNDING ACCESS
WITH
HEALTHCARE PROVIDERS AND PAYERS HAVE BEEN COMPLETED
    * MORE ARE EXPECTED IN EARLY-LAUNCH COUNTRIES OVER COURSE OF
2021

Source text for Eikon:  ID:nWkr44pGm1 
Further company coverage:  HNSA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))